<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03441048</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00031633</org_study_id>
    <nct_id>NCT03441048</nct_id>
  </id_info>
  <brief_title>Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase I Study of Lintuzumab-Ac225 in Combination With CLAG-M Chemotherapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-center phase I clinical study aimed at determining the&#xD;
      maximum-tolerated dose and safety of Lintuzumab-Ac225 in combination with CLAG-M chemotherapy&#xD;
      in the management of relapsed/refractory acute myeloid leukemia. This study uses a 3+3 design&#xD;
      to estimate the maximum-tolerated dose (MTD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Relapsed/refractory acute myeloid leukemia (RR-AML) in adults is an important therapeutic&#xD;
      challenge. Nearly 60% of AML patients ultimately relapse or have refractory disease, and&#xD;
      failure to achieve remission in this population is almost universally fatal. Therefore, a&#xD;
      critical need exists for the development of novel therapies.&#xD;
&#xD;
      Currently, for RR-AML, many institutions utilize the chemotherapy regimen of CLAG-M&#xD;
      (cladribine, cytarabine, G-CSF, mitoxantrone) based on a reported morphological complete&#xD;
      remission (CR) rate of 58% in prospective clinical trials. Because of this, and its favorable&#xD;
      performance when compared with outcomes reported for other regimens utilized in RR-AML, we&#xD;
      believe enhancing the efficacy of CLAG-M is a rational approach to improve therapy in RR-AML.&#xD;
&#xD;
      A promising approach that could enhance the clearance of leukemic blasts when added to CLAG-M&#xD;
      chemotherapy is a monoclonal antibody radioconjugate directed against markers expressed in&#xD;
      leukemic cells. Radiation has known cytotoxic properties in chemo-resistant AML. The benefit&#xD;
      of an antibody radioconjugate would be leukemic specific delivery of potent radiotherapy with&#xD;
      potentially minimal systemic off-target side-effects. One such antibody radioconjugate is&#xD;
      Lintuzumab-Ac225, a highly cytotoxic alpha radiation emitter that targets the cluster of&#xD;
      differentiation 33 (CD33) cell surface antigen, which is expressed on leukemic cells.&#xD;
&#xD;
      In this novel study, we aim to add the radioconjugated antibody Lintuzumab-Ac225 to salvage&#xD;
      CLAG-M chemotherapy in order to improve the treatment response for patients with RR-AML.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of subjects with dose-limiting toxicities.</measure>
    <time_frame>28 Days</time_frame>
    <description>Dose-escalation will be conducted according to a 3+3 design. The initial dose of Lintuzumab-Ac225 will be 0.25 micro-Curie (μCi)/kg (Dose level 1), and the highest dose administered will be 1.25 μCi/kg.&#xD;
if 0/3 pts have no dose-limiting toxicity (DLT), new patients enter next dose level.&#xD;
if 1/3 pts has DLT, 3 pts treated at same dose level.&#xD;
if 0/3 pts at that dose level has DLT, new pts enter higher level.&#xD;
if 1 or more of the additional 3 pts has a DLT, no further pts started at dose level, preceding dose is the MTD.&#xD;
if 2/3 of initially dosed patients have a DLT on first dose, study terminated.&#xD;
if 0/3 have DLT at highest dose, additional 3 enrolled.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum-tolerated dose.</measure>
    <time_frame>28 Days</time_frame>
    <description>Defined as the dosage with the highest level at which no more than 1/6 experience a DLT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of subjects who have at least one serious adverse event related to the study.</measure>
    <time_frame>1 Year</time_frame>
    <description>All subjects who receive study drug will be closely monitored for serious adverse events (SAEs). The NCI's CTCAE (Common Toxicity Criteria for Adverse Effects) v4.03 will be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of subjects with a complete response (CR).</measure>
    <time_frame>Up to Day 60</time_frame>
    <description>A complete response will be defined as bone marrow blasts &lt;5% with absolute neutrophil count ≥1000/μL and platelet ≥100,000/μL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of subjects with CR with incomplete hematologic recovery (CRi)</measure>
    <time_frame>Up to Day 60</time_frame>
    <description>CRi is defined as CR without platelet recovery or neutrophil recovery. This will be defined as bone marrow blasts &lt;5% with absolute neutrophil count &lt;1000/L and platelet &lt;100,000/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of subjects in a morphologic leukemia-free state (MLFS).</measure>
    <time_frame>Up to Day 60</time_frame>
    <description>MLFS is bone marrow blasts &lt;5% with absolute neutrophil count &lt;1000/μL AND platelet &lt;100,000/μL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of subjects experiencing partial remission.</measure>
    <time_frame>Up to Day 60</time_frame>
    <description>Partial remission (PR) is defined by a decrease of at 50% or more in the percentage of blasts to less than 25% in the bone marrow. and normalized blood counts ( ANC&gt;1000, Platelets&gt;100,000/ml).</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Lintuzumab Ac225 (Dose 1 - 0.25 μCi/kg Ac-225 with 1.6 μg/kg lintuzumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lintuzumab Ac225 (Dose 2 - 0.50 μCi/kg Ac-225 with 3.2 μg/kg lintuzumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lintuzumab Ac225 (Dose 3 - 0.75 μCi/kg Ac-225 with 4.7μg/kg lintuzumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lintuzumab Ac225 (Dose 4 - 1.00 μCi/kg Ac-225 with 6.4 μg/kg lintuzumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lintuzumab Ac225 (Dose 5 - 1.25 μCi/kg Ac-225 with 8.0 μg/kg lintuzumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lintuzumab-Ac-225 (Dose 1: 0.25 μCi/kg Ac-225 with 1.6 μg/kg lintuzumab)</intervention_name>
    <description>Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.</description>
    <arm_group_label>Lintuzumab Ac225 (Dose 1 - 0.25 μCi/kg Ac-225 with 1.6 μg/kg lintuzumab)</arm_group_label>
    <other_name>HuM195-Ac225</other_name>
    <other_name>Actimab-A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>Cladribine 5mg/m^2/day IV over two hours on days 2-6.</description>
    <arm_group_label>Lintuzumab Ac225 (Dose 1 - 0.25 μCi/kg Ac-225 with 1.6 μg/kg lintuzumab)</arm_group_label>
    <arm_group_label>Lintuzumab Ac225 (Dose 2 - 0.50 μCi/kg Ac-225 with 3.2 μg/kg lintuzumab)</arm_group_label>
    <arm_group_label>Lintuzumab Ac225 (Dose 3 - 0.75 μCi/kg Ac-225 with 4.7μg/kg lintuzumab)</arm_group_label>
    <arm_group_label>Lintuzumab Ac225 (Dose 4 - 1.00 μCi/kg Ac-225 with 6.4 μg/kg lintuzumab)</arm_group_label>
    <arm_group_label>Lintuzumab Ac225 (Dose 5 - 1.25 μCi/kg Ac-225 with 8.0 μg/kg lintuzumab)</arm_group_label>
    <other_name>Leustatin</other_name>
    <other_name>Mavenclad</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Cytarabine 2 gm/m^2/day IV over four hours on days 2-6.</description>
    <arm_group_label>Lintuzumab Ac225 (Dose 1 - 0.25 μCi/kg Ac-225 with 1.6 μg/kg lintuzumab)</arm_group_label>
    <arm_group_label>Lintuzumab Ac225 (Dose 2 - 0.50 μCi/kg Ac-225 with 3.2 μg/kg lintuzumab)</arm_group_label>
    <arm_group_label>Lintuzumab Ac225 (Dose 3 - 0.75 μCi/kg Ac-225 with 4.7μg/kg lintuzumab)</arm_group_label>
    <arm_group_label>Lintuzumab Ac225 (Dose 4 - 1.00 μCi/kg Ac-225 with 6.4 μg/kg lintuzumab)</arm_group_label>
    <arm_group_label>Lintuzumab Ac225 (Dose 5 - 1.25 μCi/kg Ac-225 with 8.0 μg/kg lintuzumab)</arm_group_label>
    <other_name>Cytosar-U</other_name>
    <other_name>Depocyt</other_name>
    <other_name>cytosine arabinoside (ara-C)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone</intervention_name>
    <description>Mitoxantrone 10mg/m^2/day IV on days 2-4.</description>
    <arm_group_label>Lintuzumab Ac225 (Dose 1 - 0.25 μCi/kg Ac-225 with 1.6 μg/kg lintuzumab)</arm_group_label>
    <arm_group_label>Lintuzumab Ac225 (Dose 2 - 0.50 μCi/kg Ac-225 with 3.2 μg/kg lintuzumab)</arm_group_label>
    <arm_group_label>Lintuzumab Ac225 (Dose 3 - 0.75 μCi/kg Ac-225 with 4.7μg/kg lintuzumab)</arm_group_label>
    <arm_group_label>Lintuzumab Ac225 (Dose 4 - 1.00 μCi/kg Ac-225 with 6.4 μg/kg lintuzumab)</arm_group_label>
    <arm_group_label>Lintuzumab Ac225 (Dose 5 - 1.25 μCi/kg Ac-225 with 8.0 μg/kg lintuzumab)</arm_group_label>
    <other_name>Mitozantrone</other_name>
    <other_name>Novantrone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>G-CSF at a dose of 300 µg on days 1-6.</description>
    <arm_group_label>Lintuzumab Ac225 (Dose 1 - 0.25 μCi/kg Ac-225 with 1.6 μg/kg lintuzumab)</arm_group_label>
    <arm_group_label>Lintuzumab Ac225 (Dose 2 - 0.50 μCi/kg Ac-225 with 3.2 μg/kg lintuzumab)</arm_group_label>
    <arm_group_label>Lintuzumab Ac225 (Dose 3 - 0.75 μCi/kg Ac-225 with 4.7μg/kg lintuzumab)</arm_group_label>
    <arm_group_label>Lintuzumab Ac225 (Dose 4 - 1.00 μCi/kg Ac-225 with 6.4 μg/kg lintuzumab)</arm_group_label>
    <arm_group_label>Lintuzumab Ac225 (Dose 5 - 1.25 μCi/kg Ac-225 with 8.0 μg/kg lintuzumab)</arm_group_label>
    <other_name>colony-stimulating factor 3 (CSF 3)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lintuzumab-Ac-225 (Dose 2: 0.50 μCi/kg Ac-225 with 3.2 μg/kg lintuzumab)</intervention_name>
    <description>Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.</description>
    <arm_group_label>Lintuzumab Ac225 (Dose 2 - 0.50 μCi/kg Ac-225 with 3.2 μg/kg lintuzumab)</arm_group_label>
    <other_name>HuM195-Ac225</other_name>
    <other_name>Actimab-A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lintuzumab-Ac-225 (Dose 3: 0.75 μCi/kg with 4.7μg/kg lintuzumab)</intervention_name>
    <description>Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.</description>
    <arm_group_label>Lintuzumab Ac225 (Dose 3 - 0.75 μCi/kg Ac-225 with 4.7μg/kg lintuzumab)</arm_group_label>
    <other_name>HuM195-Ac225</other_name>
    <other_name>Actimab-A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lintuzumab-Ac-225 (Dose 4: 1.00 μCi/kg with 6.4 μg/kg lintuzumab)</intervention_name>
    <description>Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.</description>
    <arm_group_label>Lintuzumab Ac225 (Dose 4 - 1.00 μCi/kg Ac-225 with 6.4 μg/kg lintuzumab)</arm_group_label>
    <other_name>HuM195-Ac225</other_name>
    <other_name>Actimab-A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lintuzumab-Ac-225 (Dose 5: 1.25 μCi/kg with 8.0 μg/kg lintuzumab)</intervention_name>
    <description>Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.</description>
    <arm_group_label>Lintuzumab Ac225 (Dose 5 - 1.25 μCi/kg Ac-225 with 8.0 μg/kg lintuzumab)</arm_group_label>
    <other_name>HuM195-Ac225</other_name>
    <other_name>Actimab-A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years at the time of informed consent.&#xD;
&#xD;
          2. Morphologically documented primary AML or secondary AML [from prior conditions such as&#xD;
             Myelodysplastic Syndrome (MDS), myeloproliferative neoplasm (MPN)] or therapy related&#xD;
             AML (t-AML), as defined by World Health Organization (WHO) criteria.&#xD;
&#xD;
          3. In first or subsequent relapse or refractory status after prior therapy, with or&#xD;
             without prior hematopoietic stem cell transplant (HSCT). Patients with MDS and&#xD;
             progression to AML on hypomethylating agents will also be included.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance score 0-2.&#xD;
&#xD;
          5. Greater than 25% of blasts must be CD33 positive on flow cytometry using Phycoerythrin&#xD;
             (PE) labeled anti-CD33 antibody.&#xD;
&#xD;
          6. Patients must meet the following clinical laboratory criteria:&#xD;
&#xD;
               -  Total bilirubin ≤ 2 x the upper limit of the normal range (ULN)&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN.&#xD;
&#xD;
               -  Calculated creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
               -  Resting left ventricular ejection fraction (LVEF) &gt; 40%&#xD;
&#xD;
          7. Female patients must agree to avoid becoming pregnant, and male patients should avoid&#xD;
             impregnating a female partner.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute Promyelocytic Leukemia.&#xD;
&#xD;
          2. Active severe infection not well controlled by antibacterial or antiviral therapy.&#xD;
&#xD;
          3. Known infection with human immunodeficiency virus.&#xD;
&#xD;
          4. Patients with documented pulmonary disease, with a diffusing capacity of the lungs for&#xD;
             carbon monoxide (DLCO) and/or forced expiratory volume in one second (FEV1) &lt;65%, or&#xD;
             history of dyspnea at rest, or requiring oxygen.&#xD;
&#xD;
          5. Pregnant or breast feeding women.&#xD;
&#xD;
          6. Prior chemotherapy or radiotherapy within 14 days of study entry unless fully&#xD;
             recovered from adverse effects due to treatment, at investigator's discretion.&#xD;
&#xD;
          7. Active malignancy within 2 years of entry, except previously treated melanoma grade 2&#xD;
             or less, non-melanoma skin cancer, carcinoma in situ, or cervical intraepithelial&#xD;
             neoplasia, and organ confined prostate cancer with no evidence of progressive disease&#xD;
             based on prostate-specific antigen (PSA) levels and are not on active therapy. Active&#xD;
             malignancy is malignancy receiving treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sameem Abedin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical College of Wisconsin Cancer Center Clinical Trials Office</last_name>
    <phone>414-805-8900</phone>
    <email>cccto@mcw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Froedtert Hospital and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Center Clinical Trials Office</last_name>
      <phone>866-680-0505</phone>
      <phone_ext>8900</phone_ext>
      <email>cccto@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Sameem Abedin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 15, 2018</study_first_submitted>
  <study_first_submitted_qc>February 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2018</study_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Sameem M. Abedin, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>Relapsed/refractory acute myeloid leukemia</keyword>
  <keyword>CLAG-M</keyword>
  <keyword>Lintuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Cladribine</mesh_term>
    <mesh_term>Lintuzumab</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

